Financial Data and Key Metrics Changes - In Q4, the company achieved positive and adjusted EBITDA along with positive cash flow, marking a significant milestone towards profitability [9] - Revenue growth for Q4 was nearly 26% compared to the same quarter of the previous year, while full-year revenue growth was close to 22% [14] Business Line Data and Key Metrics Changes - The pathology division's revenues exceeded the breakeven point of $1.3 million per month for the second consecutive quarter, with a target run rate of approximately $25 million by the end of 2025 [16] - The products division's Q4 revenues remained stable at $700,000, with ongoing customer onboarding processes affecting revenue recognition [17][18] Market Data and Key Metrics Changes - The company anticipates a gradual increase in revenue share generated through its distributor network versus direct sales, aiming for scalable growth [37] Company Strategy and Development Direction - The company aims to shift its mindset from a defensive to an offensive approach, viewing expenditures as investments for future growth [13] - A revitalized distribution strategy is in place to create new opportunities for scalable growth beyond direct sales [44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in overcoming challenges related to regulatory changes, equipment processes, and personnel issues, emphasizing a proactive approach to customer onboarding [31][32] - The company is focused on enhancing visibility within financial markets and aims to provide clearer insights into its growth trajectory [40][42] Other Important Information - The return of Steve Miller as Chief Commercial Officer is expected to accelerate growth in the products division, leveraging his extensive background in the diagnostic field [35] Q&A Session Summary - No specific questions or answers were provided in the content, thus this section is not applicable.